Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns
Third Harmonic Bio Inc (NASDAQ:THRD) will discontinue the ongoing Phase 1b study of THB001 in chronic inducible urticaria, after observing asymptomatic…
Third Harmonic Bio Announces Discontinuation Of Phase 1b Study Of THB001 In Chronic Inducible Urticaria
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID
-- Evidence of clinical activity observed; full data set to be presented at
Jefferies Initiates Coverage On Third Harmonic Bio with Buy Rating, Announces Price Target of $30
Jefferies analyst Akash Tewari initiates coverage on Third Harmonic Bio (NASDAQ:THRD) with a Buy rating and announces Price Target of $30.
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers
Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Tesla, ABB And Other Big Losers From Monday
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session.
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.